Cargando…

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruggiero, Angelo, Picone, Vincenzo, Martora, Fabrizio, Fabbrocini, Gabriella, Megna, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392468/ https://www.ncbi.nlm.nih.gov/pubmed/35996400 http://dx.doi.org/10.2147/CCID.S364640

Ejemplares similares

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
por: Ruggiero, Angelo, et al.
Publicado: (2021)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

A case of linear psoriasis in a young patient with Down syndrome and review of the literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study
por: Megna, Matteo, et al.
Publicado: (2023)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data
por: Ruggiero, Angelo, et al.
Publicado: (2023)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
por: Megna, Matteo, et al.
Publicado: (2022)

Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

A Case of New-Onset Lichen Planus after COVID-19 Vaccination
por: Picone, Vincenzo, et al.
Publicado: (2022)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
por: Martora, Fabrizio, et al.
Publicado: (2022)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab
por: Du Jardin, Kristian Garn, et al.
Publicado: (2020)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Risankizumab for psoriasis
Publicado: (2020)

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis
por: Ruggiero, Angelo, et al.
Publicado: (2021)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series()
por: Megna, Matteo, et al.
Publicado: (2022)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Pemphigus vulgaris and COVID‐19 vaccination: Management and treatment
por: Martora, Fabrizio, et al.
Publicado: (2022)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_083ibiiia83curounpagefs7se